The document was signed on the MUW side by Prof. Piotr Pruszczyk, Vice Rector for Science and Technology Transfer. On the part of the Human Biome Institute, the agreement was signed by its founders - Dr. Jaroslaw Bilinski, Prof. Grzegorz Basak and Grzegorz Stefanski, MD.
The Human Biome Institute was established as a result of the commercialization of scientific research conducted by Dr. Jaroslaw Bilinski and Prof. Grzegorz Basak from the Chair and Department of Hematology, Transplantation and Internal Medicine UCC MUW, as a spin-off from the Medical University of Warsaw. - We believe that the collaboration will create, competitive to world leaders, a scientific platform for unique research and discovery in this field and create an ecosystem in which top-level science can be commercialized. We model ourselves on the world's best science and business ecosystems like Harvard, Cambridge, Oxford, Stanford - said Dr. Jaroslaw Bilinski, and added that several collaborative studies are already underway with more projects in the pipeline.
The Human Biome Institute is the first biotechnology company in Poland and one of the few in Europe to research the gut microbiome as a new type of biotherapeutic. The company plans to develop Next Generation Biotherapeutics (BNG) - therapeutic products containing bacteria, bacteriophages (live biotherapeutic products), proteins and metabolites/postbiotics. This is a pioneering approach on a global scale - the creation of a complementary product, applied sequentially, in a well-defined manner, based on natural components of the gut microbiota selected using highly specialized computational methods. The flagship product the company is working on is a BNG that fights antibiotic-resistant bacteria. The second leading product is BNG administered for the prevention and treatment of graft-versus-host disease, a severe complication of bone marrow transplantation. - The researchers, MUW staff and founders of the company are among the world leaders and pioneers in the use of gut microbiota transplantation for this indication and antibiotic resistance. We are currently working on a more advanced form of therapy - says Dr. Bilinski.